Upstream Bio (NASDAQ:UPB) Stock Price Up 9.4% – Should You Buy?

Upstream Bio, Inc. (NASDAQ:UPB) shot up 9.4% on Tuesday . The company traded as high as $28.41 and last traded at $28.5660. 307,233 shares were traded during trading, a decline of 50% from the average session volume of 608,514 shares. The stock had previously closed at $26.12.

Analyst Upgrades and Downgrades

UPB has been the topic of a number of recent analyst reports. Truist Financial began coverage on shares of Upstream Bio in a research report on Tuesday, October 14th. They issued a “buy” rating and a $47.00 target price on the stock. Lifesci Capital began coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price for the company. Evercore initiated coverage on Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Finally, Mizuho raised Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Upstream Bio Price Performance

The company’s 50 day simple moving average is $29.12 and its 200 day simple moving average is $23.25. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -14.79 and a beta of 1.89.

Hedge Funds Weigh In On Upstream Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bain Capital Life Sciences Investors LLC raised its holdings in Upstream Bio by 6.3% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock valued at $26,786,000 after acquiring an additional 144,216 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Upstream Bio by 57.5% during the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after purchasing an additional 235,958 shares during the last quarter. Norges Bank purchased a new stake in shares of Upstream Bio during the 2nd quarter worth $10,650,000. Virtus Investment Advisers LLC acquired a new position in shares of Upstream Bio during the second quarter worth $89,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in Upstream Bio by 133.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock valued at $86,000 after buying an additional 4,483 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.